Primary adrenal sarcomas: A national analysis of epidemiological trends, treatment patterns, and outcomes
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Bibek Aryal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Sarcoma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives Primary adrenal sarcoma (PAS) is an exceedingly rare malignancy with limited data available on its epidemiology, management, and outcomes. This study aimed to characterize the national incidence, treatment patterns, and survival of PAS utilizing a National Cancer Database.
Methods
The National Cancer Database was queried for patients diagnosed with primary adrenal tumors from 2004 to 2019. Cases with sarcoma histology were identified as PAS. Annual incidence trends, histological distribution, treatment modalities (surgery, chemotherapy, radiation therapy), perioperative outcomes, and overall survival (OS) were analyzed.
Results
Of 7213 primary adrenal tumor cases, 332 (4.6%) were PAS. The most common histological subtypes were leiomyosarcoma (37.3%), hemangiosarcoma (27.1%), and sarcoma not otherwise specified (6.0%). Most cases (71.7%) presented as locoregional disease. Treatment included surgery alone (47.8%), surgery plus chemotherapy and/or radiation (27.1%), chemotherapy/radiation alone (13.3%), or no treatment (13.9%). For surgical cases, the median length of stay was 5 days, the 30‐day readmission rate was 3.36%, and the 30/90‐day mortality rates were 3.65% and 9.90%, respectively. The 5‐year OS rate for surgery alone was 43%, with a median OS of 34.6 months. For surgery with radiation/chemotherapy, the 5‐year OS rate was 37.3%, with a median OS of 35.4 months.
Conclusions
This largest analysis of PAS to date demonstrates that most cases present as locoregional disease amenable to surgical resection, with favorable outcomes. The role of adjuvant therapy remains unclear, as no significant survival difference was observed between surgery alone and multimodal treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Surgery Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Cancer Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Zitieren
APA
Aryal, B., Falls, S., Yin, Y., Wagner, P. L., Bartlett, D. L., Wegner, R. E., & Allen, C. J. (2024). Primary adrenal sarcomas: A national analysis of epidemiological trends, treatment patterns, and outcomes. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27836
Vancouver
Aryal B, Falls S, Yin Y, Wagner PL, Bartlett DL, Wegner RE, et al. Primary adrenal sarcomas: A national analysis of epidemiological trends, treatment patterns, and outcomes. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27836
BibTeX
@article{Aryal2024,
author = {Aryal, Bibek and Falls, Samantha and Yin, Yue and Wagner, Patrick L and Bartlett, David L and Wegner, Rodney E and Allen, Casey J},
title = {Primary adrenal sarcomas: A national analysis of epidemiological trends, treatment patterns, and outcomes},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27836}
}
EUVIMED